Floatz logo

Paliperidone Palmitate 3-Month Formulation

Sexual Dysfunction

Si TianmeiPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Sexual Dysfunction cohort.

Asset / SponsorPhaseRating
Tadalafil
University of Roma La Sapienza
Phase 4BBB
TESTOSTERONE UNDECYLATE
Alliance for Clinical Trials in Oncology
Phase 3BB
TAMOXIFEN
Irmandade da Santa Casa de Misericordia de Sao Paulo
Phase 4BB
Risperdal
Si Tianmei
Phase 4BB
Cimicifuga Racemosa
Irmandade da Santa Casa de Misericordia de Sao Paulo
Phase 4BB

View all 27 →

Same molecule, other indications

Paliperidone Palmitate 3-Month Formulation is also rated in:

schizoaffective disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
76 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →